These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37615760)

  • 1. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
    Donners R; Tunariu N; Tovey H; Hall E; Chua S; Cook G; Du Y; Blackledge MD; Parker CC; Koh DM
    Eur Radiol; 2024 Feb; 34(2):1146-1154. PubMed ID: 37615760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake of Radium-223 Dichloride and Early [
    Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N
    Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Assessment of Early [
    Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R
    J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-Body [
    Muzi M; O'Sullivan F; Perk TG; Muzi JP; Mankoff DA; Jeraj R; Duan F; Yu EY
    Tomography; 2021 Apr; 7(2):139-153. PubMed ID: 33923126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer.
    Roth AR; Harmon SA; Perk TG; Eickhoff J; Choyke PL; Kurdziel KA; Dahut WL; Apolo AB; Morris MJ; Perlman SB; Liu G; Jeraj R
    Clin Genitourin Cancer; 2019 Aug; 17(4):306-314. PubMed ID: 31221545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
    Lin C; Bradshaw T; Perk T; Harmon S; Eickhoff J; Jallow N; Choyke PL; Dahut WL; Larson S; Humm JL; Perlman S; Apolo AB; Morris MJ; Liu G; Jeraj R
    J Nucl Med; 2016 Dec; 57(12):1872-1879. PubMed ID: 27445292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223.
    Scalzi P; Baiocco C; Genovese S; Trevisan A; Sirotova Z; Poti C
    Urologia; 2017 Feb; 84(1):61-64. PubMed ID: 27911459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of [
    Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Relationship Between Total Lesion Activity on
    Filippi L; Basile P; Schillaci O; Bagni O
    Cancer Biother Radiopharm; 2020 Aug; 35(6):398-403. PubMed ID: 32109140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [
    Azad GK; Taylor BP; Green A; Sandri I; Swampillai A; Harries M; Kristeleit H; Mansi J; Goh V; Cook GJR
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):821-830. PubMed ID: 30506455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline
    García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
    Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
    Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM
    J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
    Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
    J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of [
    Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of
    Murray I; Chittenden SJ; Denis-Bacelar AM; Hindorf C; Parker CC; Chua S; Flux GD
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1832-1844. PubMed ID: 28612079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of bone flare on
    Weisman AJ; Harmon SA; Perk TG; Eickhoff J; Choyke PL; Kurdziel KA; Dahut WL; Humm JL; Apolo AB; Larson SM; Morris MJ; Perlman SB; Liu G; Jeraj R
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):324-330. PubMed ID: 30413807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observer Agreement and Accuracy of
    Zacho HD; Fonager RF; Nielsen JB; Haarmark C; Hendel HW; Johansen MB; Mortensen JC; Petersen LJ
    J Nucl Med; 2020 Mar; 61(3):344-349. PubMed ID: 31481577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
    Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
    Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.